Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 11:33 PM ET


Company Overview of Marinus Pharmaceuticals, Inc.

Company Overview

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marin...

100 Matsonford Road

Three Radnor Corporate Center

Suite 304

Radnor, PA 19087

United States

Founded in 2003

9 Employees



Key Executives for Marinus Pharmaceuticals, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 58
Total Annual Compensation: $455.0K
Chief Financial Officer, Vice President, Treasurer and Secretary
Age: 44
Total Annual Compensation: $405.0K
Chief Medical Officer
Age: 50
Compensation as of Fiscal Year 2014.

Marinus Pharmaceuticals, Inc. Key Developments

Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures

Marinus Pharmaceuticals, Inc. announced that it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. Sites participating in this global study have completed screening patients. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. The company anticipates announcing top-line results from the study in mid-2016. The global, randomized, placebo-controlled Phase 3 study is designed to evaluate the effectiveness and safety of ganaxolone as an adjunctive therapy in adults with drug-resistant focal onset seizures. Approximately 350 patients will be randomized to receive either 1,800 mg/day of ganaxolone or placebo for 12 weeks. The primary endpoint of the study is percent change in seizure frequency per 28 days relative to the baseline. Further information about the Phase 3 study can be found on, using Identifier NCT01963208.

Marinus Pharmaceuticals, Inc. Announces Executive Appointments

Marinus Pharmaceuticals, Inc. announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Both individuals will report to the company’s Chief Medical Officer, Albena Patroneva, M.D. Dr. Lappalainen is a U.S. board certified psychiatrist with extensive experience in clinical practice and medical research. Most recently, Lappalainen served as Executive Director, Drug Development Services at Premier Research CRO, where he oversaw the safety and medical monitoring of clinical trials and provided consultations on clinical trial design and drug development. Most recently, McCormick served as Senior Director, Global Regulatory Affairs, Lifitegrast and ADHD/Vyvanse New Uses for Shire Pharmaceuticals.

Marinus Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 08:00 AM

Marinus Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 08:00 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Christopher Michael Cashman, Executive Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
US WorldMeds, LLC United States
MKHS Investor LLC United States
Actavis South Atlantic LLC United States
Recursion Pharmaceuticals, LLC United States
CBA Pharma, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Marinus Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at